TW202532441A - 用來治療患有類風濕性關節炎之個體的方法及組成物 - Google Patents

用來治療患有類風濕性關節炎之個體的方法及組成物

Info

Publication number
TW202532441A
TW202532441A TW113147810A TW113147810A TW202532441A TW 202532441 A TW202532441 A TW 202532441A TW 113147810 A TW113147810 A TW 113147810A TW 113147810 A TW113147810 A TW 113147810A TW 202532441 A TW202532441 A TW 202532441A
Authority
TW
Taiwan
Prior art keywords
antibody
antigen
sarilumab
subject
binding portion
Prior art date
Application number
TW113147810A
Other languages
English (en)
Chinese (zh)
Inventor
安妮塔 博亞帕蒂
尼爾 格拉漢
敏夫 木村
傑若 密西德
Original Assignee
美商再生元醫藥公司
法商賽諾菲生物技術公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商再生元醫藥公司, 法商賽諾菲生物技術公司 filed Critical 美商再生元醫藥公司
Publication of TW202532441A publication Critical patent/TW202532441A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
TW113147810A 2018-08-29 2019-08-28 用來治療患有類風濕性關節炎之個體的方法及組成物 TW202532441A (zh)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201862724212P 2018-08-29 2018-08-29
US62/724,212 2018-08-29
US201862747301P 2018-10-18 2018-10-18
US62/747,301 2018-10-18
US201962798697P 2019-01-30 2019-01-30
US62/798,697 2019-01-30
US201962824399P 2019-03-27 2019-03-27
US62/824,399 2019-03-27
US201962856431P 2019-06-03 2019-06-03
US62/856,431 2019-06-03
US201962858443P 2019-06-07 2019-06-07
US62/858,443 2019-06-07
EP19192387 2019-08-19
EP19192387.9 2019-08-19

Publications (1)

Publication Number Publication Date
TW202532441A true TW202532441A (zh) 2025-08-16

Family

ID=67851236

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113147810A TW202532441A (zh) 2018-08-29 2019-08-28 用來治療患有類風濕性關節炎之個體的方法及組成物
TW108130759A TWI868074B (zh) 2018-08-29 2019-08-28 用來治療患有類風濕性關節炎之個體的方法及組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108130759A TWI868074B (zh) 2018-08-29 2019-08-28 用來治療患有類風濕性關節炎之個體的方法及組成物

Country Status (16)

Country Link
US (2) US11319375B2 (https=)
EP (1) EP3843852A1 (https=)
JP (1) JP7504871B2 (https=)
KR (1) KR20210049871A (https=)
CN (1) CN112955222A (https=)
AU (2) AU2019329958B2 (https=)
BR (1) BR112021003206A2 (https=)
CA (1) CA3110891A1 (https=)
CL (1) CL2021000483A1 (https=)
IL (1) IL280824A (https=)
MA (1) MA53481A (https=)
MX (2) MX2021002422A (https=)
PH (1) PH12021550416A1 (https=)
SG (1) SG11202101674QA (https=)
TW (2) TW202532441A (https=)
WO (1) WO2020047029A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
FR3095698B1 (fr) * 2019-05-03 2021-05-07 Sinnovial Procédé d’estimation de l’efficacité de traitement par un agent anti-CD20 chez un patient atteint de polyarthrite rhumatoïde et en réponse inadéquate a au moins une biothérapie
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
CA3180369A1 (en) * 2020-05-26 2021-12-02 Inka Albrecht Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
KR20230031015A (ko) * 2021-08-26 2023-03-07 주식회사 이뮨메드 자가면역질환의 예방 또는 치료를 위한 항체의약품
CN117138126B (zh) * 2023-08-30 2024-04-09 江苏恰瑞生物科技有限公司 定向清除炎症因子il-6的过滤材料及过滤柱

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP1857553A1 (en) 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
ES2384222T3 (es) 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
UA66757C2 (en) 1996-02-26 2004-06-15 Advanced Res & Tech Inst Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
DE60025744D1 (de) 1999-10-07 2006-04-13 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
FR2920033B1 (fr) 2007-08-13 2014-08-22 Snecma Turbomachine avec diffuseur
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010106812A1 (en) 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2011006273A1 (en) * 2009-07-15 2011-01-20 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112012028557A2 (pt) 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
CN103370081A (zh) 2011-02-03 2013-10-23 桑塔鲁斯股份有限公司 受试者的选择和治疗
TWI568888B (zh) 2011-09-15 2017-02-01 第諾拉工業公司 氣體擴散電極及其製法和電化電解池
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US9387246B2 (en) * 2013-09-03 2016-07-12 L. Douglas Graham Treatment methods for rheumatoid arthritis
MX377190B (es) 2013-11-22 2025-03-07 Sanofi Biotechnology Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
WO2015116852A1 (en) * 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
AU2015317905A1 (en) 2014-09-16 2017-03-16 Regeneron Pharmaceuticals, Inc. Compositions for improving the health related quality of life of rheumatoid arthritis patients
WO2017079443A1 (en) 2015-11-03 2017-05-11 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
CA3016880A1 (en) * 2016-03-07 2017-09-14 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis

Also Published As

Publication number Publication date
MX2025010592A (es) 2025-10-01
JP7504871B2 (ja) 2024-06-24
AU2019329958B2 (en) 2025-05-29
US20200102395A1 (en) 2020-04-02
TWI868074B (zh) 2025-01-01
US11319375B2 (en) 2022-05-03
AU2019329958A1 (en) 2021-03-18
CN112955222A (zh) 2021-06-11
CL2021000483A1 (es) 2021-07-19
US20230059376A1 (en) 2023-02-23
KR20210049871A (ko) 2021-05-06
BR112021003206A2 (pt) 2021-05-25
MA53481A (fr) 2021-07-07
IL280824A (en) 2021-04-29
AU2025203365A1 (en) 2025-05-29
CA3110891A1 (en) 2020-03-05
EP3843852A1 (en) 2021-07-07
TW202026035A (zh) 2020-07-16
MX2021002422A (es) 2021-07-15
SG11202101674QA (en) 2021-03-30
WO2020047029A1 (en) 2020-03-05
PH12021550416A1 (en) 2021-09-27
JP2022502350A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
US20230059376A1 (en) Methods and compositions for treating subjects having rheumatoid arthritis
JP6250109B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
US20260108601A1 (en) Method of diagnosis and treatment of rheumatoid arthritis
RU2828027C2 (ru) Способы диагностики и лечения ревматоидного артрита
WO2015116852A1 (en) Methods for treating rheumatoid arthritis by administering an il-6r antibody
EA053078B1 (ru) Способы и композиции для лечения субъектов, страдающих ревматоидным артритом
EA045703B1 (ru) Способы и композиции для лечения субъектов, страдающих ревматоидным артритом